Entry into a Material Definitive Agreement

Business Context and Reporting Period

This Form 8-K Current Report was filed by Ekso Bionics Holdings, Inc. (not Chronoscale Holdings Corp) on February 6, 2014. The filing reports the completion of the third and final closing of a private placement offering (PPO) previously disclosed on January 23, 2014.

Key Financial Metrics

The filing details a specific capital raise event rather than ongoing operational financials. Key metrics include:

  • Securities Issued: 2,863,500 Units.
  • Purchase Price: $1.00 per Unit.
  • Unit Composition: One share of Common Stock ($0.001 par value) and one warrant to purchase one share at $2.00 per share (5-year term).
  • Gross Proceeds: $2,863,500.
  • Estimated Fees and Expenses: Approximately $286,350 (10% placement agent fee).
  • Net Proceeds: Approximately $2,577,150 (calculated as gross proceeds minus estimated fees).

Note: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or overall liquidity position.

Material Changes

The primary material change is the increase in equity capital and the corresponding dilution of existing shareholders due to the issuance of 2,863,500 new shares and associated warrants. This transaction represents the final tranche of the PPO.

Guidance, Outlook, and Risks

Management Commentary and Terms:

  • Anti-Dilution Protection: Investors in the Units and PPO Warrants received weighted average anti-dilution protection if the Company issues shares below $1.00 within 24 months of the final closing (subject to customary exceptions).
  • Placement Agent Compensation: Gottbetter Capital Markets, LLC received 10% cash commissions and warrants to purchase 10% of the shares sold (2% for certain named investors) at an exercise price of $1.00 per share.
  • Registration Rights: Investors became parties to a Registration Rights Agreement dated January 15, 2014.
  • Exemption: The offering was conducted under Section 4(a)(2) of the Securities Act and Regulation D, sold to accredited investors on a "best efforts" basis.

Risks and Contingencies: The filing includes standard disclaimers that representations and warranties in the exhibits are for the benefit of the parties to the agreements and may not reflect the actual state of affairs or materiality standards for general investors.

Investor Verification Checklist

  • Verify the total aggregate capital raised across all closings of the PPO (this filing covers only the final $2.86M tranche).
  • Review the specific terms of the anti-dilution protection to understand potential future dilution scenarios.
  • Confirm the exact number of warrants issued to the placement agent and their impact on the fully diluted share count.
  • Check subsequent filings for the use of proceeds and the Company's updated cash position.
  • Review the Registration Rights Agreement to understand the timeline for potential public registration of these shares.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.